Today: 21 May 2026
AMD Stock Forecast 2026: Wall Street Sees 32% Upside as CES Keynote Nears
2 January 2026
2 mins read

AMD Stock Forecast 2026: Wall Street Sees 32% Upside as CES Keynote Nears

NEW YORK, January 1, 2026, 18:01 ET

  • AMD starts 2026 near $214, with analysts’ average target implying a roughly 32% upside.
  • CEO Lisa Su is due to headline CES days into the new year, a key early catalyst for chip stocks.
  • The 2026 setup hinges on AI infrastructure spending and whether customers keep capital outlays steady.

As 2026 begins, Wall Street’s average 12-month price target for Advanced Micro Devices (AMD.O) sits at $282.82, implying about 32% upside from $214.16, according to Investing.com data.

That forecast lands days before a closely watched stage appearance. AMD said CEO Lisa Su will deliver the company’s CES 2026 keynote on Jan. 5 at 9:30 p.m. ET, ahead of the Las Vegas tech show that runs Jan. 6-9.

The broader backdrop is an equity market leaning heavily on artificial intelligence (AI) narratives and corporate profit growth. The S&P 500 rose more than 16% in 2025 and S&P 500 earnings are projected up over 15% in 2026, Tajinder Dhillon, head of earnings research at LSEG, told Reuters. “If companies start to pull back on the capex … the market loses confidence in the returns that the AI investment will generate,” said Jeff Buchbinder, chief equity strategist at LPL Financial. Reuters

A price target is an analyst’s estimate of where a stock could trade over the next 12 months. It is typically based on expected sales, profit and a valuation multiple.

For AMD, the split between optimistic and cautious forecasts reflects the high stakes around AI accelerators. Investors are trying to judge whether demand for data-center chips will widen beyond the largest buyers and stay resilient through 2026.

AMD has been framing 2026 as a proving year for its next wave of AI hardware. At a November analyst day in New York, the company said it expected annual data center chip revenue of $100 billion within five years and planned to launch its next-generation MI400 series of AI chips in 2026, Reuters reported. 

In a separate Nov. 11 press release, AMD said its upcoming “Helios” systems with Instinct MI450 series GPUs are expected to begin in the third quarter of 2026. It also said the MI350 series has already been deployed at scale by leading cloud providers, including Oracle Cloud Infrastructure. Advanced Micro Devices, Inc.

GPUs, short for graphics processing units, are specialised processors widely used to train and run AI models. “Rack-scale” refers to linking many chips and networking inside a server rack so the hardware operates as one larger system.

AMD’s push puts it in direct competition with Nvidia (NVDA.O), which dominates the market for high-end AI processors. Nvidia’s CES 2026 event page says it will be in Las Vegas from Jan. 5-9 to showcase AI-focused products and partnerships.

Outside AI accelerators, AMD also competes with Intel (INTC.O) in central processors for servers and PCs. Those segments can swing with enterprise budgets and consumer upgrades, adding a cyclical layer to the 2026 outlook.

Investors will listen at CES for any update that tightens the timeline for new chip rollouts and the scale of customer commitments. They will also watch for signals on pricing and supply, which can change quickly when demand surges.

The key downside risk remains a pullback in customer capital spending, particularly at cloud and enterprise buyers funding AI infrastructure. Any sign of slower deployments would pressure the growth assumptions embedded in analysts’ targets.

For now, AMD enters 2026 with a buy-weighted Street view and an early-year spotlight at CES. The next milestones will be measured in product execution and evidence that AI momentum is translating into durable revenue growth through 2026.

Stock Market Today

  • SpaceX IPO Filing Reveals Financials, Musk Could Become First Trillionaire
    May 20, 2026, 7:08 PM EDT. SpaceX filed for an initial public offering (IPO), disclosing its finances and board members for the first time. The company reported $18.7 billion in revenue for 2025, up 33% year-on-year, but posted a net loss of $4.9 billion, reversing a $791 million profit in 2024. First-quarter 2026 losses reached $4.3 billion on $4.7 billion revenue. The IPO, trading as SPCX, may become the largest ever, potentially boosting Elon Musk's wealth to trillionaire status. SpaceX aims to fund its ambitious plans including Starlink satellite network expansion, AI infrastructure, and establishing extraterrestrial colonies.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Coca-Cola stock (KO) sits near $70 as New Year’s Day shuts markets — what Wall Street watches next
Previous Story

Coca-Cola stock (KO) sits near $70 as New Year’s Day shuts markets — what Wall Street watches next

Tesla stock ends 2025 lower as Musk charity share gift surfaces ahead of deliveries
Next Story

Tesla stock ends 2025 lower as Musk charity share gift surfaces ahead of deliveries

Go toTop